Core Insights - ResMed Inc (NYSE: RMD) has achieved double-digit revenue and profit growth over the past 9 years, contrasting with the single-digit revenue growth typical in its sector, primarily due to continuous acquisitions [1] Company Performance - The company has consistently outperformed its industry peers by leveraging strategic acquisitions to drive growth [1] Industry Context - The sector in which ResMed operates is characterized by single-digit revenue growth, highlighting the company's exceptional performance relative to its industry [1]

Key Takeaways The S&P 500 ended 0.3% lower on Wednesday, Sept. 18, as the Federal Reserve announced its first interest-rate cut since March 2020. ResMed shares tumbled after analysts said the likely label expansion of popular weight-loss drugs to treat sleep apnea could hurt demand for the company's devices. General Motors stock increased as the carmaker introduced adapters allowing drivers to power up GM EVs using Tesla's charging station network. Major U.S. equities indexes ended lower on Wednesday after ...

A looming threat from a very powerful rival could significantly dampen a key business for the company. Healthcare technology company ResMed's (RMD -5.12%) stock wasn't quite the picture of health on Wednesday. The shares lost more than 5% of their value on news of an analyst's downgrade and his new, bearish outlook. That performance didn't look good against that of the S&P 500 index, which fell a comparatively light 0.3%. A change in recommendation for the worse Well before market open that day, Wolfe Resea ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial . It's time to revisit a company I haven't covered in quite a while. As the title of this article gave away, that company is ResMed (NYSE: RMD ) , a fast-growing healthcare company. Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the comp ...

ResMed Inc.'s (RMD) growth is backed by its impressive global Mask sales growth. Of late, the company has been experiencing increased Device sales, reflecting the ongoing combined availability of AirSense 10 and AirSense 11 sleep devices. However, concerns loom over ResMed's escalating debt level and the adverse impact of macroeconomic challenges. In the past year, this Zacks Rank #3 (Hold) company's shares have surged 66.9% compared with 16.9% growth of the industry. The S&P 500 composite rose 21.1% during ...

Learn more about ResMed's 2030 strategy to accelerate growth Join in person or via virtual webcast SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As previously announced, the event will be held at the New York Stock Exchange in New York City and simultaneously webcast online. More information about this event, including access to the live webcast link (available ...

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, beginning at approximately 10:00 a.m. (Eastern Daylight Time) at the New York Marriott Marquis in New York, NY. More information about this event, including access to the live, audio-only webca ...

Market Overview - The S&P 500 increased by 0.2% on August 27, ahead of Nvidia's earnings report and key economic data releases later in the week [1][2] - Major U.S. equity indexes, including the Nasdaq, also saw gains, with the Dow achieving a record high close [2] Company Performances - ResMed's shares surged by 7.3%, driven by a positive outlook for the sleep apnea devices market, which is expected to grow at a compound annual growth rate (CAGR) of 8.5% [3] - Insulet's shares rose by 6.6% following FDA approval of its Omnipod 5 insulin pump for type 2 diabetes, marking it as the first automated insulin delivery system approved for both type 1 and type 2 diabetes [4] - Travel industry stocks gained after Trip.com reported better-than-expected quarterly sales and profits, with Royal Caribbean Cruises, Norwegian Cruise Line, and Carnival seeing increases of 4.3%, 3.6%, and 2.7% respectively [5] Declining Stocks - Walgreens Boots Alliance experienced a 9.0% drop in shares after Eli Lilly announced a cheaper version of its weight-loss treatment, raising concerns about Walgreens' sales [6] - Paramount Global's shares fell by 7.2% after media executive Edgar Bronfman Jr. withdrew his acquisition proposal, leading to uncertainties about the company's future [7] - Martin Marietta Materials saw a 4.3% decline in shares, despite a price target increase from Morgan Stanley, due to insider share sales indicating potential lack of confidence [8]

DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the world Board appointment brings over 30 years of strategic and operational finance expertise SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed's regularly scheduled board meeting on August 15, 2024 ...

FX Empire Logo English check-icon Italiano Español Português Deutsch العربية Français Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial ...